Abstract

BackgroundIt has been well known that anti-TNF-α treatment for patients with rheumatoid arthritis (RA) is associated with anti-nuclear antibody (ANA) development. Using data of 110 RA patients treated with infliximab...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Chikashi Terao ... Masao Tanaka
Seminars in Arthritis and Rheumatism | VOL. 49
Chikashi Terao, et. al.Chikashi Terao ... Masao Tanaka
10 Feb 2019
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
Ilse E A Hoffman ... Filip De Keyser
Arthritis and rheumatism | VOL. 48
Ilse E A Hoffman, et. al.Ilse E A Hoffman ... Filip De Keyser
01 Apr 2003
FRI0288 Immunogenicity is Associated with Lupus-Like Autoimmunity in Rheumatoid Arthritis Patients Treated with Infliximab
S Kondoh-Ishikawa ... M Furu
Annals of the Rheumatic Diseases | VOL. 73
S Kondoh-Ishikawa, et. al.S Kondoh-Ishikawa ... M Furu
01 Jun 2014
POS0493 TRIPLE-POSITIVITY AND ANTINUCLEAR ANTIBODIES, INSIGHTS ON DISEASE ACTIVITY: A RETROSPECTIVE COHORT STUDY OF COLOMBIAN RA PATIENTS
P A Mendez Patarroyo ... D V Verano Castillo
-
P A Mendez Patarroyo, et. al.P A Mendez Patarroyo ... D V Verano Castillo
19 May 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers